New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:37 EDTTWTR, CYTK, INCY, DISH, CLDXOptions with increasing implied volatility: CYTK CLDX INCY TWTR DISH
News For CYTK;CLDX;INCY;TWTR;DISH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 18, 2015
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
06:04 EDTTWTRTwitter implied volatility of 37 at lower end of index mean range
March 17, 2015
16:00 EDTTWTROptions Update; March 17, 2015
iPath S&P 500 VIX Short-Term Futures down 11c to 27.30. Option volume leaders: AAPL RIG MGM HTZ TWTR TSLA CY KO NFLX C according to Track Data.
11:23 EDTDISHApple willing to share TV data to attract programming partners, NY Post reports
Subscribe for More Information
10:02 EDTDISHHigh option volume stocks
High option volume stocks: NGL ARCO ENR OIL SNI ESPR CYH WIN CRZO DISH
10:00 EDTTWTROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
09:34 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
09:10 EDTDISHDISH announces four new A+E Network channels
Dish's (DISH) Sling TV announced that four A+E Networks’ channels -- A&E, HISTORY, H2 and Lifetime -- will be available in its “Best of Live TV” core package by the end of March. The company’s core package will remain priced at $20 per month. With this update also comes the introduction of two new add-on packs, “Lifestyle Extra” and “World News Extra,” each priced at an additional $5 per month. Sling TV will announce A+E Networks’ launch date and Video-On-Demand availability within the coming weeks. Sling TV plans to provide existing “News & Info Extra” subscribers with both the “Lifestyle Extra” and “World News Extra” for a total of $5 per month. A&E is jointly owned by Disney (DIS) and Hearst.
09:07 EDTDISHDISH's Sling TV launches on Xbox One
Subscribe for More Information
08:13 EDTCLDXCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
05:32 EDTINCYIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
March 16, 2015
16:25 EDTTWTRTwitter initiated with a Buy at Brean Capital
Target $61.
16:00 EDTTWTROptions Update; March 16, 2015
Subscribe for More Information
13:56 EDTTWTRChances of Twitter launching fee-based service increasing, analyst says
Subscribe for More Information
11:53 EDTDISHDISH abused small business program in auction, FCC Commissioner says
FCC Commissioner Ajit Pai stated: "Last month, the FCC’s Wireless Telecommunications Bureau disclosed that two companies in which DISH Network Corp. has an 85% ownership stake are claiming over $3B in taxpayer-funded discounts on licenses they won during the AWS-3 spectrum auction. As I said then, allowing DISH, which has annual revenues of approximately $14B and a market capitalization of over $34B, to obtain billions of dollars in taxpayer subsidies would make a mockery of the small business program. The evidence of abuse continues to mount. DISH recently disclosed that it made approximately $8.504B in loans and $1.274B in equity contributions to those two companies—hardly a sign that they were 'very small businesses' that lacked access to deep pockets. Moreover, we now know that DISH’s abuse of the program had an enormous impact on actual small businesses serving actual customers." Reference Link
10:50 EDTTWTRKing Digital seen benefiting from user base larger than Twitter, LinkedIn
Subscribe for More Information
09:37 EDTTWTRActive equity options trading on open
Subscribe for More Information
08:37 EDTTWTRTwitter verified offering becoming more likely, says Pacific Crest
Subscribe for More Information
06:11 EDTTWTRTwitter blocks Meerkat access to social network data, Buzzfeed says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use